Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
19.15
Nov 17 • 3:59 PM ET Dollar change+11.68 Percentage change(156.36%)
Aftermarket Close
17.10
Aftermarket • 7:59 PM ET Dollar change-2.05 Percentage change(-10.70%)
Today, 10:00 PMSELLAS says galinpepimut-S cut risk of death 41% in its Phase 3 AML trial
Index
RUT
Market Cap
3.90B
Enterprise Value
3.77B
Income
-35.76M
Sales
0.00M
Book/sh
0.65
Cash/sh
0.66
Employees
13
IPO
Mar 12, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
29.57
P/C
28.96
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.92
Current Ratio
14.92
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.10
EPS next Q
-0.05
EPS this Y
20.00%
EPS next Y
52.50%
EPS next 5Y
-
EPS past 3/5Y
51.28% 34.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
30.50%
Sales Y/Y TTM
-
EPS Q/Q
20.45%
Sales Q/Q
-
Insider Own
1.11%
Insider Trans
0.00%
Inst Own
35.41%
Inst Trans
5.10%
ROA
-37.13%
ROE
-40.31%
ROIC
-27.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
91.98%
SMA50
73.98%
SMA200
115.73%
Trades
Shs Outstand
203.53M
Shs Float
201.59M
52W High
15.88 20.62%
52W Low
1.39 1277.70%
Volatility
19.15% 13.37%
ATR (14)
2.15
RSI (14)
76.59
Beta
2.76
Rel Volume
17.30
Avg Volume
6.95M
Volume
120,291,755
Perf Week
128.79%
Perf Month
82.55%
Perf Quarter
38.27%
Perf Half Y
152.31%
Perf YTD
407.96%
Perf Year
1258.16%
Perf 3Y
1840.22%
Perf 5Y
170.86%
Perf 10Y
-99.62%
Prev Close
7.47
Price
19.15
Change %
156.36%
Consensus
Strong Buy
Avg. Price Target
$37.50
Implied Upside
+95.8%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 21, 2021Initiated
CCantor Fitzgerald
Overweight$18-6.0%
Nov 01, 2018Initiated
OPY logoOOppenheimer
Outperform
Apr 02, 2018Initiated
HH.C. Wainwright
Buy$11-42.6%
Mar 19, 2018Upgrade
MMaxim Group
Hold → Buy$13-32.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kalin Katherine BachDirectorNov 19 '25Buy1.5963,400100,806104,400Nov 21 08:45 AM
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
ScD h.c.Dr. Angelos M. Stergiou M.D.
Senior VP & CFOMr. John Thomas Burns CPA
MBADr. Dragan Cicic M.D.
VPMs. Stacy E. Yeung
Senior VP of Regulatory AffairsMr. Andrew Elnatan